Skip to main content
OpenTrials

Clinical trial condition

Insulin-Like Growth Factor I, Resistance To

Explore clinical trials studying Insulin-Like Growth Factor I, Resistance To. Study availability and eligibility vary by location and protocol.

14 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Insulin-Like Growth Factor I, Resistance To trial results

Completed

A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma

NCT00924989

Conditions
Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +11 more
Locations
  • TGen Clinical Research Service at Scottsdale Healthcare Scottsdale, Arizona, United States
  • University of Southern California Los Angeles, California, United States
  • UCLA Los Angeles, California, United States
  • University of Colorado Denver Cancer Center Aurora, Colorado, United States
View all 35 locations
View Trial Details
Completed

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

NCT00889382

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +15 more
Locations
  • Mayo Clinic Scottsdale, Arizona, United States
  • Department of Obstetrics and Gynecology, University of California, Irvine Orange, California, United States
  • Horizon Oncology Center Lafayette, Indiana, United States
  • Ochsner Clinic Foundation New Orleans, Louisiana, United States
View all 46 locations
View Trial Details
Completed

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

NCT00630552

Conditions
Adenocarcinoma of the Pancreas, Digestive System Diseases, Digestive System Neoplasms, +9 more
Locations
  • Research Site Alhambra, California, United States
  • Research Site Bakersfield, California, United States
  • Research Site Fullerton, California, United States
  • Research Site La Jolla, California, United States
View all 44 locations
View Trial Details
Completed

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

NCT00684983

Conditions
Breast Diseases, Breast Neoplasms, HER2 Positive Breast Carcinoma, +9 more
Locations
  • Providence Hospital Mobile, Alabama, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Alta Bates Summit Medical Center-Herrick Campus Berkeley, California, United States
  • Mills-Peninsula Medical Center Burlingame, California, United States
View all 390 locations
View Trial Details

Related conditions